| Database ID | Agent | Target | Cancer Type | Detail |
| DB00946 | erlotinib | Epidermal growth factor receptor | pancreatic cancer | view |
| DB00947 | bevacizumab | Vascular endothelial growth factor | renal cell carcinoma | view |
| DB00948 | everolimus | Serine/threonineprotein kinase mTOR | advanced solid tumors | view |
| DB00949 | pazopanib | Plateletderived growth factor receptor
Mast/stem cell growth factor receptor
Vascular endothelial growth factor receptor 2 | thyroid cancer | view |
| DB00950 | cixutumumab | Insulinlike growth factor I receptor | breast cancer | view |
| DB00951 | pazopanib | Plateletderived growth factor receptor
Mast/stem cell growth factor receptor
Vascular endothelial growth factor receptor 2 | thyroid cancer | view |
| DB00952 | cetuximab | Epidermal growth factor receptor | colorectal cancer | view |
| DB00953 | sunitinib | FL cytokine receptor
Mast/stem cell growth factor receptor
Vascular endothelial growth factor receptor 2
Plateletderived growth factor receptor | renal cell carcinoma | view |
| DB00954 | sorafenib | Vascular endothelial growth factor receptor 1
BRaf protooncogene serine/threonineprotein kinase
Protooncogene tyrosineprotein kinase receptor ret | renal cell carcinoma | view |
| DB00955 | nivolumab | programmed death1 | renal cell carcinoma | view |
| DB00956 | nivolumab | programmed death1 | melanoma | view |
| DB00957 | ipilimumab | Cytotoxic Tlymphocyte antigen 4 (CTLA4) | pancreatic cancer | view |
| DB00958 | sirolimus/rapamycin | Serine/threonineprotein kinase mTOR | advanced solid tumors | view |
| DB00959 | bevacizumab erlotinib | NA | non small cell lung cancer | view |
| DB00960 | lenvatinib | Alpha plateletderived growth factor receptor
Mast/stem cell growth factor receptor
Protooncogene tyrosineprotein kinase receptor ret
VEGF receptor
Fibroblast growth factor receptor | renal cell carcinoma | view |